{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-102314","form_type":"8-K","ticker":"VCEL","cik":"0000887359","company_name":"Vericel Corp","filed_at":"2023-09-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.890986+00:00","generated_at":"2026-06-10T12:47:07.378299+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vericel launches NexoBrid in U.S. for severe thermal burns; $300M addressable market","bullets":["Full commercial launch of NexoBrid for eschar removal in adults with deep partial/full-thickness thermal burns.","Selective enzymatic debridement preserves viable tissue vs. surgical excision.","Addressable U.S. market of ~30,000 patients/year, equating to $300 million.","Product can be applied in up to two 4-hour sessions covering up to 20% total body surface area.","Launch expands Vericel's Burn Care franchise and diversifies revenue stream."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-102314","json":"https://secwatch.observer/filing/0001104659-23-102314.json","markdown":"https://secwatch.observer/filing/0001104659-23-102314.md","text":"https://secwatch.observer/filing/0001104659-23-102314.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/887359/000110465923102314/0001104659-23-102314-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/887359/000110465923102314/tm2326562d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T12:47:07.378299+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}